Biologics CDMO Market Report: By Product Type (Drug Product, Drug Substance), Cell Line Type (Microbial, Mammalian, Viral Vector & Other Modalities), Service Type (Clinical, Commercial) – Global Industry Revenue Estimation and Demand Forecast to 2030

Market Overview

The global biologics CDMO market size was estimated at $13,173.7 million in 2021. This number is expected to increase to $31,839.7 million by 2030, at a CAGR of 10.3% during 2021–2030. This can be ascribed to the rising demand for medicines, increasing and aging population, heavy investment in healthcare infrastructure, and launch of new products.

Essentially, due to the rising incidence of infectious diseases and high demand for novel therapeutics, pharma and biotech organizations that need to put in higher capital investments for advanced technologies are developing partnerships with CDMOs.

Drug Substances Contribute More than Half the Revenue to market

Drug substances held the largest revenue share, of over 50.0%, in 2021, and they are projected to stay on this path during the forecast period. This will be owing to an increase in biologics approvals, particularly by the FDA, as well as the strong clinical pipelines and reducing biologic drug development failure rates. Most of the outsourcing revenue from drug substance production comes from the monoclonal antibody (mAb) sub-segment.

The drug product category will grow faster in the market in the years to come. This can be ascribed to CDMOs' platform strength and low technical and IP-related concerns, which is why the pharmaceutical sector is progressively embracing drug product outsourcing.

Mammalian Cell Line Type Dominates Market

Mammalian cell culture is expected to contribute revenue of $17,983 million in 2030 to the biologics CDMO market, advancing with a CAGR of over 10.0% during 2021–2030. As more-complex biologics, such as antibody–drug conjugates and bi- and tri-specific antibodies, are developed, this category will grow. Because of their effectiveness in treating numerous diseases, including cancer, mAbs and their synthetic equivalents have received large investments. mAbs have traditionally been developed from mammalian cells for the treatment of diseases like these.

Increasing Investment in R&D Will Boost Market Growth

According to the EFPIA, the pharmaceutical industry invested $46,144 million in 2020 in Europe for researching, developing, and bringing new medicines. The increasing demand for pharmaceutical drugs and biologics, as well as the advanced production requirements, have prompted CDMOs to engage in R&D. Moreover, R&D supports the development and testing of novel therapies, product portfolio expansions, and clinical testing for safety and marketing. Hence, the increasing investment in research and product development will propel the growth of the biologics CDMO market.

During the pandemic, the heightened need for vaccines and therapeutic antibodies positively affected the market. Furthermore, the pandemic revealed supply chain flaws and the world’s reliance on emerging markets, such as China and India, for APIs and generics. These factors have impelled countries to boost domestic manufacturing, to meet the supply, which CDMOs can benefit from.

Moreover, demand for clinical services is increasing in the market due to the adoption of outsourcing by the biopharmaceutical industry to mitigate the accompanying risks in the drug development phase with bio-CDMOs’ low development costs and high expertise. Moreover, the increasing number of collaborations with small and clinical-stage biopharma enterprises, which account for a significant portion of the biopharma clinical pipeline, enhanced the growth of the market.

Explore more about this report - Request free sample pages

APAC Remains Most-Lucrative Region for CDMOs Manufacturing Biologics

An emerging market, APAC attracts the attention of biologics contract development and manufacturing organizations. Geographically, APAC is the largest and fastest-growing region in the biologics CDMO market, with a CAGR of over 10.0% throughout the forecast period. This is due to a massive and rapidly rising population, which is demanding improved access to medicines. Furthermore, the region's growth in the market is being driven, in part, by the increasing affordability of pharmaceuticals as a result of the emergence of low-cost generics. Additionally, an increase in GDP per capita, government healthcare programs, and rise in the urbanization rate, all of which have expanded the access to doctors and pharmacies for significant portions of the population, are making CDMOs prosperous.

For example, India is an excellent country for the CDMO market as it has received the FDA approval for a vast number of drug items and has a highly qualified and skilled workforce. As the access to healthcare improves in emerging economies and the number of generic manufacturers in India grows, there will be a huge increase in the business of local CDMOs, as India can handle an enormous number of products more cost-effectively. Essentially, the growth of the market is aided by the expansion of the healthcare infrastructure in the country.

Key Players in Biologics CDMO Market:

• Boehringer Ingelheim International GmbH
• WuXi Biologics (Cayman) Inc.
• Samsung Biologics
• Lonza Group Ltd.
• FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
• Toyobo Co. Ltd.
• Parexel International Corporation
• BINEX Co. Ltd.
• JRS Pharma LP
• Sandoz International GmbH (Novartis AG)

Market Size Breakdown by Segment

The report offers comprehensive market segmentation analysis along with market estimation for the period 2017–2030.

Based on Product Type

• Drug Product    
• Drug Substance

Based on Cell Line Type

• Microbial
• Mammalian       
• Viral Vector & Other Modalities

Based on Service Type

• Clinical
• Commercial

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
• Asia-Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America (LATAM)
  • Brazil
  • Mexico
• Middle East and Africa (MEA)
  • Saudi Arabia
  • South Africa